Publications by authors named "Margalida Rotger"

41Publications

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.

Antimicrob Agents Chemother 2017 01 27;61(1). Epub 2016 Dec 27.

Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.00899-16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192124PMC
January 2017

Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.

J Antimicrob Chemother 2016 07 29;71(7):1933-42. Epub 2016 Mar 29.

Division of Clinical Pharmacology, University Hospital Centre and University of Lausanne, Lausanne, Switzerland School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkw050DOI Listing
July 2016

In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.

Drug Metab Dispos 2016 Jan 9;44(1):151-61. Epub 2015 Nov 9.

Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.065839DOI Listing
January 2016

Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression.

AIDS 2014 Jun;28(9):1261-72

aAIDS Research Institute -IrsiCaixa-iInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain bInstitute of Microbiology, University Hospital Center and University of Lausanne, Lausanne cUniversity Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland dUniversidad Complutense de Madrid, Madrid, Spain eMonogram Biosciences, South San Francisco, California, USA fCentre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Badalona gBanc de Sang i Teixits, Barcelona hUniversitat de Vic (UVic-UCC), Vic iInstitució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. *Judith Dalmau and Margalida Rotger contributed equally to this article. †Amalio Talenti, Javier Martinez-Picado and Julia G. Prado contributed equally to the work.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000000293DOI Listing
June 2014

Efavirenz intoxication due to a new CYP2B6 constellation.

Antivir Ther 2013 2;18(5):739-43. Epub 2013 May 2.

Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP2571DOI Listing
June 2014

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

Clin Infect Dis 2013 Jul 26;57(1):112-21. Epub 2013 Mar 26.

Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/cit196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669528PMC
July 2013

Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.

Pharmacogenet Genomics 2013 Feb;23(2):84-93

Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neurosciences,University Hospital Center, University of Lausanne, Lausanne.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/jpharmacogenetics/2013/02000/Co
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/FPC.0b013e32835cb2e2DOI Listing
February 2013

Dosage optimization of treatments using population pharmacokinetic modeling and simulation.

Chimia (Aarau) 2012 ;66(5):291-5

Department of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2533/chimia.2012.291DOI Listing
September 2012

Pharmacogenomics: what is next?

Front Pharmacol 2011 13;2:86. Epub 2012 Jan 13.

Institute of Microbiology, University Hospital, University of Lausanne Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2011.00086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257847PMC
March 2012

Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.

Pharmacogenomics 2010 Apr;11(4):587-94

Infectious Disease Service, Infektiologie & Spitalhygiene, Kantonsspital Bruderholz, University of Basel, 4101 Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs.10.35
Publisher Site
http://dx.doi.org/10.2217/pgs.10.35DOI Listing
April 2010

[General concepts and study methods in pharmacogenetics].

Enferm Infecc Microbiol Clin 2008 May;26 Suppl 6:4-9

Institute of Microbiology, University Hospital Center, University of Lausanne, Suiza.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0213-005x(08)76506-6DOI Listing
May 2008

Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

Eur J Clin Pharmacol 2008 Apr 11;64(4):335-6. Epub 2008 Jan 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-007-0440-zDOI Listing
April 2008

Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7.

Pharmacogenet Genomics 2007 Oct;17(10):885-90

Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne; Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e3282ef5cd1DOI Listing
October 2007

Does tenofovir influence efavirenz pharmacokinetics?

Antivir Ther 2007 ;12(1):115-8

Institute of Microbiology, University Hospital, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
June 2007

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Curr HIV/AIDS Rep 2006 Sep;3(3):118-25

Institute of Microbiology and University Hospital, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF02696655DOI Listing
September 2006

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

J Infect Dis 2005 Oct 9;192(8):1381-6. Epub 2005 Sep 9.

Institute of Microbiology and Service of Infectious Diseases, University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/466531DOI Listing
October 2005

Phenotypic and genotypic mupirocin resistance among Staphylococci causing prosthetic joint infection.

J Clin Microbiol 2005 Aug;43(8):4266-8

Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JCM.43.8.4266-4268.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234000PMC
August 2005

In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus.

Antimicrob Agents Chemother 2005 Aug;49(8):3187-91

Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.49.8.3187-3191.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1196268PMC
August 2005